ArticleMolecular neurobiology2026
Ellagitannin Metabolite Urolithin D Ameliorates Cognitive Function and Behavioral Performance in Aging Mice Partially via AMPK/PGC-1α/SIRT3-Dependent Regulation of Mitophagy-Related Molecular Machinery.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the protective effects of gut-derived urolithin D (Uro D) against neurodegenerative lesions in a D-galactose (D-gal)-induced chemical aging mouse model and its underlying molecular mechanisms. In vivo, mice received 8-week daily intraperitoneal injection of 150 mg/kg D-gal plus oral gavage of 50-150 mg/kg/day Uro D. The regulatory protein networks in related pathways and structural features of mitophagy-associated proteins were further explored. A D-gal-induced cellular stress model in HT22 neuronal cells was established to evaluate mitochondrial parameters, protein expression levels, and alterations in mitophagy-related molecular machinery. In vivo, Uro D treatment improved cognitive performance and behavioral impairment, reduced hippocampal pathology, preserved synaptic plasticity, and alleviated aging symptoms. Mechanistically, Uro D upregulated AMPK, PGC-1α, and mitochondrial SIRT3 expression to modulate mitochondrial functional activity. Uro D modulates mitophagy-associated signaling, accompanied by altered expression of Beclin1, LC3, P62, Parkin, and PINK1. Further in vitro experiments suggested that Uro D enhances mitochondrial integrity in cellular stress models. Progressive normalization of mitochondrial shape, oxidative stress, and calcium ion homeostasis contribute to the alleviation of pathological symptoms associated with aging. SIRT3 knockdown in HT22 cells increased mitochondrial damage and suppressed the activation of mitophagy-related molecular machinery. Further results from AMPK/PGC-1α inhibition and SIRT3 rescue experiments revealed that inhibition of AMPK or PGC-1α abolished the protective effects of Uro D, whereas SIRT3 overexpression alleviated D-gal-induced cellular abnormalities. Uro D partially triggers molecular changes consistent with mitophagy activation through the AMPK/PGC-1α/SIRT3 cascade, contributing to the mitigation of hippocampal neuronal injury and the improvement of learning and memory deficits in D-gal-induced aging mice.
Indexed as
Identifiers
42842065What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.